Alphatec launches spinal bridge
This article was originally published in The Gray Sheet
Executive Summary
Firm announces availability of its 510(k)-cleared Cross Link adjustable bridge spinal implant on July 18. The device, which Alphatec acquired through a distribution agreement with Sea Spine, will be marketed for use in combination with the firm's Zodiac polyaxial pedical screws. Alphatec went public in June, to compete with Stryker, Smith & Nephew and Abbott in the almost $3 bil. spinal fusion market (1"The Gray Sheet" July 17, 2006, p. 9)...
You may also be interested in...
Orthopedics In Brief
Medtronic set to begin spinal stabilization trial: Firm is enrolling patients for the first of three clinical trials evaluating the use of its Diam spinal stabilization system. Medtronic announced IDE clearance to begin studies of the nonfusion spinal stabilization system on July 10. Diam relieves spine pressure by rerouting spinal load, similar to St. Francis Medical's X-Stop device, PMA approved in 2005. Medtronic's initial study, slated to begin in August, will examine the safety and effectiveness of the Diam system in patients with degenerative stenosis. The second trial, to begin in Europe in September, will compare discectomy with Diam to discectomy alone. A third study will evaluate Diam's use in degenerative disc disease. Medtronic expects to enroll a total of 430 patients in up to 25 centers in the U.S. and Europe...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.